Singapore: Less Than Three Months Left For Companies To Prepare For New Pharma Rules
Singapore's efforts to consolidate and streamline the regulatory control of all health products under a single legislation has resulted in the fine-tuning of certain regulatory provisions that drug companies should be aware of.
You may also be interested in...
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.